Skip to main content
. 2020 Aug 27;106(10):2707–2719. doi: 10.3324/haematol.2020.265462

Figure 6.

Figure 6.

Effect of fetal hemoglobin induction by pomalidomide or CRISPR/Cas9 on terminal erythroid differentiation of sickle cell disease erythroblasts. (A) Percentage of cells expressing fetal hemoglobin (F-cells) at day (D) 7 and D9 of phase II of culture of culture in patient erythroblasts under normoxia (PN), hypoxia (PH), normoxia with POM [PN(POM)] and hypoxia with POM [PH(POM)] (n=4). (B) Percentage of F-cells at D7 and D9 of phase II of culture in patient erythroblasts under normoxia (PN) and hypoxia (PH) treated with guide RNA (gRNA) targeting the LRF binding site (-197) or an unrelated locus as control (AAVS1) (n=4). Genome editing efficiency was 56.1 ± 9.6% and 79.2± 2.8% for -197 and AAVS1 samples, respectively. (C) Percentage of apoptotic cells measured by flow cytometry in PN, PH, PN(POM) and PH(POM) at D7 and D9 of phase II of culture of culture (n=4). (D) Percentage of apoptotic cells at D7 and D9 of phase II of culture in patient erythroblasts under normoxia (PN) and hypoxia (PH) treated with gRNA targeting the LRF binding site (-197) or an unrelated locus as control (AAVS1) (n=4). Horizontal bars represent the mean of each group; *P<0.05, Mann-Whitney test (A, B and D).